Risankizumab Effective for Moderate to Severe Psoriasis Risankizumab Effective for Moderate to Severe Psoriasis

Response rates with the novel biologic that targets IL-23 are strong, even among obese patients, and the dosing interval is attractive, but the treatment field for plaque psoriasis is already crowded.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news